-transparent.png){kind=logo}
OBJECTIVE To compare carbamazepine pharmacokinetic parameters between obese and lean subjects following the administration of a single 200-mg tablet. METHODS Single-dose intervention, open study. METHODS Teaching university hospital. METHODS Eighteen obese (group A) otherwise healthy subjects, referred to the metabolic outpatient clinic, and 13 healthy lean (group B) volunteers. Inclusion criterion for the obese subjects was a body mass index (BMI = weight/height2) of more than 30 kg/m2. In the obese group, mean +/- SD total body weight (TBW), BMI, and percent of ideal body weight (IBW) were 111.4 +/- 19.9 kg, 38.8 +/- 6.0 kg/m2, and 182.7% +/- 30.7%, respectively. These values were significantly greater than the respective values of 63.2 +/- 8.3 kg, 22.4 +/- 1.6 kg/m2, and 105.8% +/- 5.8% obtained in the lean group (p < 0.001). METHODS Single-dose oral administration of carbamazepine 200-mg tablet (Teril, Taro, Israel). RESULTS Carbamazepine elimination half-life (t1/2), apparent volume of distribution (Varea/F), and its oral clearance (Clpo/F) were derived from the drug concentration-time curves. RESULTS Carbamazepine Varea/F and t1/2 were significantly greater in group A than in group B (98.4 +/- 26.9 vs. 60.7 +/- 8.5 L, respectively, p < 0.001; and 59.4 +/- 14.7 vs. 31.0 +/- 5.0 h, respectively, p < 0.001), but its Clpo/F was reduced only slightly in obese as compared with lean subjects (19.8 +/- 5.2 vs. 23.0 +/- 4.6 mL/min, respectively, p = 0.07). Correction for IBW yielded similar results for Varea/F and t1/2, but Clpo/F per kg of IBW was significantly smaller in the obese than in the lean subjects (0.32 +/- 0.07 vs. 0.39 +/- 0.06 mL/min/kg of IBW, respectively, p < 0.02). Linear correlations were observed between Varea/F and TBW for both group A (r = 0.92, p < 0.001) and group B (r = 0.77, p < 0.002). CONCLUSIONS In comparison with lean subjects, carbamazepine Varea/F is significantly greater in obese subjects and its t1/2 is markedly prolonged. The minor nonsignificant effect of obesity on carbamazepine Clpo/F suggests that in obese subjects the carbamazepine daily dose should be based on IBW, not on TBW.
Y Caraco, and
E Zylber-Katz, and
E M Berry, and
M Levy
October 1965,
Annals of the New York Academy of Sciences,
Y Caraco, and
E Zylber-Katz, and
E M Berry, and
M Levy
October 2012,
Journal of veterinary pharmacology and therapeutics,
Y Caraco, and
E Zylber-Katz, and
E M Berry, and
M Levy
September 1998,
Anesthesiology,
Y Caraco, and
E Zylber-Katz, and
E M Berry, and
M Levy
June 2012,
Diabetes care,
Y Caraco, and
E Zylber-Katz, and
E M Berry, and
M Levy
November 2016,
Endocrine connections,
Y Caraco, and
E Zylber-Katz, and
E M Berry, and
M Levy
April 1984,
Nutrition reviews,
Y Caraco, and
E Zylber-Katz, and
E M Berry, and
M Levy
May 2017,
Diabetes,
Y Caraco, and
E Zylber-Katz, and
E M Berry, and
M Levy
July 2003,
Metabolism: clinical and experimental,
Y Caraco, and
E Zylber-Katz, and
E M Berry, and
M Levy
January 1965,
Metabolism: clinical and experimental,
Y Caraco, and
E Zylber-Katz, and
E M Berry, and
M Levy
August 1972,
Archives of environmental health,
